Merck Reports the P-IIb/III Study Data of Clesrovimab (MK-1654) to Prevent RSV Disease in Infants
Shots:
- Merck has reported topline data from the P-IIb/III (MK-1654-004) study assessing the safety & efficacy of clesrovimab vs PBO to prevent RSV disease among healthy preterm & full-term infants
- The study reached its 1EP of safety & effectiveness, showing a reduction in medically attended lower respiratory infections (MALRI) due to RSV at D150. Data will form the basis of filings to regulatory authorities worldwide & will be highlighted at future conferences
- Clesrovimab (MK-1654) is an extended half-life mAb intended for passive immunization to prevent lower respiratory infections due to RSV in infants
Ref: Merck | Image: Merck
Related News:- Merck’s Capvaxive Receives the US FDA’s Accelerated Approval to Prevent Invasive Pneumococcal Disease and Pneumonia in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
